Because of these benefits, SGLT-2 inhibitors are recently being used one of the first-line drugs for glucose lowering, particularly in patients with type 2 diabetes at increased cardiovascular risk [19]. Here, SLC5A2 is linked to type 2 diabetes mellitus.